Distribution of weight, stature, and growth status in children and adolescents with spinal muscular atrophy: An observational retrospective study in the United States.

"CONFLICTS OF INTEREST B.T.D. has served as an ad hoc scientific advisory board member for AveXis, Biogen, Cytokinetics, Vertex, Genentech/Roche, and Pfizer; Steering Committee Chair for Roche and DSMB member for Amicus Inc.; he has no financial interests in these companies. He has received research support from the National Institutes of Health/National Institute of Neurological Disorders and Stroke, the Slaney Family Fund for SMA, the Spinal Muscular Atrophy Foundation, CureSMA, and Working on Walking Fund and has received grants from Ionis Pharmaceuticals, Inc., for the ENDEAR, CHERISH, CS2/CS12 studies; from Biogen for CS11; and from Cytokinetics, Sarepta Pharmaceuticals, PTC Therapeutics, Scholar Rock, Fibrogen, and Summit. He has also received royalties for books and online publications from Elsevier and UpToDate, Inc. S.G., J.H., S.S., I.G., K.G., S.F‐R., and R.S.S., are employees of F. Hoffmann‐La Roche. R.S.F. has participated as an investigator in clinical trials sponsored by AveXis/Novartis Gene Therapies, Biogen, Catabasis, Cytokinetics, Ionis Pharmaceuticals, Muscular Dystrophy Association, National Institutes of Health, Lilly, ReveraGen, Roche, Sarepta, Scholar Rock, and Summit. He has received honoraria for participating in symposia and on advisory boards for these same pharmaceutical companies. The data used in this manuscript were collected prior to these engagements with Roche. He serves without compensation as an advisor to the n‐Lorem and EveryLife Foundations. His institution receives funding from Biogen for the coordination of a USA registry for SMA, iSMAC. He receives licensing fees from the Children's Hospital of Philadelphia and publishing royalty fees from Elsevier. D.C.D. has served as an advisor/consultant for AveXis, Biogen, Cytokinetics, Ionis Pharmaceuticals, Inc., Metafora, Roche, Sanofi, Sarepta, n‐lorem Foundation and the SMA Foundation; received grants from Hope for Children Research Foundation, National Institutes of Health, SMA Foundation, Cure SMA, Glut 1 Deficiency Foundation and US Department of Defense; clinical trial funding from Biogen, Mallinckrodt, PTC, Sarepta, Scholar Rock, and Ultragenyx; and as a member of the DSMB for Aspa Therapeutics."

"Funding information F. Hoffmann‐La Roche Ltd"